Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.
Emi IshikawaYuta YokoyamaHaruna ChishimaHidefumi KasaiOuki KuniyoshiMotonori KimuraJun HakamataHideo NakadaNaoya SuehiroNaoki NakayaHideo NakajimaShinnosuke IkemuraIchiro KawadaHiroyuki YasudaHideki TeraiAya JibikiHitoshi KawazoeKenzo SoejimaHiroshi MuramatsuSayo SuzukiTomonori NakamuraPublished in: Investigational new drugs (2023)
Higher exposures to osimertinib, AZ5104, and AZ7550 and polymorphisms in EGFR, ABCG2, and ABCB1 were related to higher severity of AEs; therefore, monitoring these may be beneficial for osimertinib AE management.